

21

crosslinking HA with BDDE to obtain a crosslinked HA;
 adding a free HA gel to the crosslinked HA;
 adding a solution of lidocaine HCl to the crosslinked HA; and
 autoclaving the crosslinked HA having free HA gel and lidocaine HCl added thereto, to obtain a sterile dermal filler composition.

25. A dermal filler product comprising:

a dermal filler composition comprising a hyaluronic acid (HA) crosslinked with 1,4 butanediol diglycidyl ether (BDDE), and between about 0.1% to about 5.0% lidocaine by weight, wherein the HA is not crosslinked to a non-HA biopolymer, and wherein the composition is sterile;

a syringe containing the sterile composition;

wherein the product is made by a process comprising:

crosslinking HA with BDDE to obtain a crosslinked HA;
 adding lidocaine to the crosslinked HA to obtain a crosslinked HA containing lidocaine; and

22

packaging the crosslinked HA containing lidocaine in a syringe; and

autoclaving the syringe containing the crosslinked HA containing lidocaine to obtain a dermal filler product.

26. The dermal filler product of claim **25**, wherein the sterile composition contained in the syringe has a volume between about 0.8 mL and about 2.5 mL.

27. The dermal filler product of claim **25**, wherein the sterile composition has a HA concentration of about 20 mg/mL to about 30 mg/mL.

28. The dermal filler product of claim **25**, wherein the sterile composition is stable at ambient temperature for at least about 6 months.

29. The dermal filler product of claim **25**, wherein the sterile composition comprises particles of crosslinked HA having an average particle size of at least about 200 μm .

30. The dermal filler product of claim **25**, wherein the sterile composition comprises particles of crosslinked HA having an average particle size of less than about 200 μm .

* * * * *